Drugs / LRX712
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03355196 | Nov 2017 → Mar 2019 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT04097379 | Jul 2020 → Aug 2024 | osteoarthritis, knee | Novartis Pharmaceuticals | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LRX712 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03355196 ↗ |
| Route | Other | “LRX712 given intra-articularly” NCT03355196 ↗ |